Coeptis Therapeutics News

Buy Rating for Coeptis Therapeutics Holdings Amidst Promising Cancer Cell Therapy Platforms and Exclusive Licensing Assets

TipRanksNov 14, 2023 14:05 ET

Ladenburg Thalmann Initiates Coverage On Coeptis Therapeutics With Buy Rating, Announces Price Target of $3

BenzingaSep 22, 2023 07:49 ET

Coeptis Therapeutics Analyst Ratings

BenzingaSep 22, 2023 07:48 ET

EF Hutton Assumes Coeptis Therapeutics at Buy, Maintains Price Target of $10

BenzingaMay 25, 2023 09:04 ET

EF Hutton Reiterates Buy on Coeptis Therapeutics, Maintains $6 Price Target

BenzingaMay 18, 2023 04:47 ET

JonesTrading Keeps Their Buy Rating on Coeptis Therapeutics Holdings (COEP)

TipRanksMay 11, 2023 11:15 ET

EF Hutton Reiterates Buy on Coeptis Therapeutics, Maintains $6 Price Target

BenzingaMay 10, 2023 05:28 ET

JonesTrading Initiates Coverage On Coeptis Therapeutics With Buy Rating, Announces Price Target of $4

BenzingaApr 19, 2023 05:02 ET

Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), Coeptis Therapeutics Holdings (COEP) and Day One Biopharmaceuticals (DAWN)

TipRanksApr 5, 2023 08:46 ET

EF Hutton Reiterates Buy on Coeptis Therapeutics, Maintains $6 Price Target

BenzingaApr 5, 2023 04:34 ET

EF Hutton Reiterates Buy on Coeptis Therapeutics, Maintains $6 Price Target

BenzingaMar 29, 2023 10:38 ET

Coeptis Therapeutics Analyst Ratings

Benzinga Analyst RatingsDec 13, 2022 06:38 ET

EF Hutton Initiates Coverage On Coeptis Therapeutics With Buy Rating, Announces Price Target of $6

Benzinga Real-time NewsDec 13, 2022 06:38 ET

Coeptis Therapeutics Analyst Ratings

Benzinga Analyst RatingsDec 12, 2022 07:44 ET

EF Hutton Initiates Coverage On Coeptis Therapeutics With Buy Rating, Announces Price Target of $6

Benzinga Real-time NewsDec 12, 2022 07:44 ET